## Yes — and the missing baseline is the story, not a hole in it

You don't need a before/after chart to prove reliability at scale. You need proof the system holds up in production, under real load, over real time — and Helio gives you all three: 2.1M events/day, 99.97% delivery, five months of live patient-scheduling traffic. The one thing you don't have (legacy throughput/error numbers) is itself a legitimate, honest data point: their old pipeline was never instrumented. Lead with that instead of hiding it — "we went from no visibility to full visibility" is a stronger, more credible claim than a fabricated percentage improvement, and it's the kind of admission a technical reader trusts more, not less.

Below is the full draft, ready for Marcus's review. Two things are flagged inline as placeholders, not fact: his direct quotes (I've drafted illustrative language, but nothing here should ship as an attributed quote until he's said it in his own words) and Helio's boilerplate/compliance posture (confirm before publishing — patient-scheduling data likely means legal should sign off on any claim, even implicit, about what kind of data flows through the pipeline).

---

## Page Copy

**Meta title:** Helio Diagnostics: 2.1M Events a Day, 99.97% Delivery in Production | [Company] Case Study
**Meta description:** How Helio Diagnostics runs patient-scheduling traffic on [Company]'s ingest SDK — five months in production, fully measured, 99.97% delivery at 2.1M events/day.

### Headline
**From No Visibility to 99.97% Delivery: How Helio Diagnostics Runs Patient Scheduling on [Company]**

### Subheadline
Helio's legacy ingest pipeline had no dashboards and no error-rate baseline — not because it was failing, but because no one had ever measured it. Five months into production on real patient-scheduling traffic, they can now measure everything: 2.1M events a day, delivered at 99.97%.

### Snapshot bar
- **2.1M** events processed per day
- **99.97%** delivery rate
- **5 months** in production
- **100%** real patient-scheduling traffic — no staging, no shadow rollout

### The Challenge — Flying blind by design
Helio Diagnostics' scheduling system moved a high volume of time-sensitive events every day, and it worked — mostly. But the legacy ingest path had never been instrumented. There were no dashboards, no throughput metrics, no error-rate tracking. The team knew the system *when it broke*; they had no way to know how it performed when it didn't.

For a pipeline carrying patient-scheduling data, that's not a minor gap. An unmeasured system is one you're trusting on faith — every day, at whatever scale it happens to be running.

### The Solution
Helio adopted [Company]'s ingest SDK to replace the legacy path, [one sentence on what specifically changed in the integration — confirm with Marcus: language migration? drop-in replacement? phased cutover?]. The migration gave the team something the old system never had: a live, measurable view of every event moving through it.

### The Result — Five months, fully measured
Helio has now run the SDK in production for five months, entirely on live patient-scheduling traffic. The numbers:

- **2.1M events/day** processed through the pipeline
- **99.97% delivery**, measured continuously, not sampled
- Zero migration back to the legacy path

> "[Draft — confirm exact wording with Marcus before use]: We never really knew what the old system's numbers were. We just knew when it broke. Now we can see everything, and what we see is a pipeline that just works."
> — **Marcus Vance, Lead Engineer, Helio Diagnostics**

### A note on the numbers
We're not showing a before/after comparison here, because one doesn't exist — Helio's legacy system was never instrumented enough to produce one. Rather than paper over that, we think it's the more honest version of this story: a five-month, unsampled, production track record on real patient-scheduling traffic is strong proof on its own, and the absence of a legacy baseline is itself evidence of what the SDK replaced.

### Final CTA
**See what your ingest pipeline actually looks like.**
[Talk to an Engineer] · [Get a Reliability Walkthrough]

---

## Annotations

- **Headline reframes the gap as the hook.** "From No Visibility to 99.97% Delivery" turns the missing baseline into the opening claim instead of an admission buried in paragraph four. It also sets up the "note on the numbers" section so a skeptical reader (an engineer evaluating you, i.e. exactly your audience) doesn't feel misled when they notice there's no comparison chart.
- **Snapshot bar leads with volume + reliability + duration + realism**, in that order — the four things a technical buyer checks before believing a vendor's numbers: scale, correctness, staying power, and "is this actually production."
- **The quote is deliberately about the absence of visibility, not a stat.** It's the most defensible, most human thing Marcus can say without inventing a comparison he doesn't have — and it does more trust-building work than a generic "great product" quote would.
- **"A note on the numbers" section exists to pre-empt the objection**, not bury it. Naming the limitation yourself, before a reader spots it, reads as confidence; letting them find it themselves reads as evasion.
- Two bracketed placeholders remain: the integration detail in "The Solution," and the quote. Both need Marcus's actual words — do not publish either as fabricated fact. Fabricated quotes or stats create legal exposure independent of the marketing risk, and Marcus already offered to go on record, so there's no reason to guess at his language.

## Alternative headlines
- **Option A:** *"2.1M Events a Day, 99.97% Delivered: Helio Diagnostics in Production"* — leads straight with the hard numbers, for a reader who wants proof before story. Loses the "no visibility" narrative hook.
- **Option B:** *"Helio Diagnostics Couldn't Measure Their Old Pipeline. Now They Can — and It's 99.97% Reliable."* — more conversational, keeps the honesty angle, slightly longer.
- **Option C (recommended, used above):** *"From No Visibility to 99.97% Delivery"* — shortest, cleanest contrast, works as a headline and as the thesis for the whole page.

## Before publishing — what to close out with Marcus
1. Get the actual quote, verbatim — ask him directly: *"What did the old system feel like to operate, day to day?"* and *"What's different now that you can actually see the numbers?"* Use his words, not the draft above.
2. Confirm the specific migration detail (what "adopting the SDK" concretely replaced) — the draft above is deliberately vague because this wasn't in what you told me.
3. Route the draft past legal/compliance before publishing anything naming "patient-scheduling data" — confirm what can be said publicly about the nature of the data, even at this level of generality, given the healthcare context.
4. Get Helio's standard case-study/logo-use approval in writing, separate from Marcus's personal sign-off to be quoted.